IRulya Therapeutics Inc. (IRLA) stock
IRLANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$39.80+0.02 (+0.05%)
Close on Nov 13, 2026Market cap $40.48MP/E –Yield –
IRulya Therapeutics ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
IRulya Therapeutics's ebitda for the twelve months ending Sep 30, 2026 was -$126.74M. For fiscal 2025 it was -$57.93M. The highest annual figure on record is -$12.07M in fiscal 2018.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$57.93M | – |
| FY2024 | Dec 31, 2024 | -$57.10M | – |
| FY2023 | Dec 31, 2023 | -$34.30M | – |
| FY2022 | Dec 31, 2022 | -$51.81M | – |
| FY2021 | Dec 31, 2021 | -$89.97M | – |
| FY2020 | Dec 31, 2020 | -$78.56M | – |
| FY2019 | Dec 31, 2019 | -$38.98M | – |
| FY2018 | Dec 31, 2018 | -$12.07M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$13.13M | – |
| Q2 FY2026 | Jun 30, 2026 | -$79.74M | – |
| Q1 FY2026 | Mar 31, 2026 | -$14.55M | – |
| Q4 FY2025 | Dec 31, 2025 | -$19.31M | – |
| Q3 FY2025 | Sep 30, 2025 | -$13.39M | – |
| Q2 FY2025 | Jun 30, 2025 | -$10.39M | – |
| Q1 FY2025 | Mar 31, 2025 | -$14.83M | – |
| Q4 FY2024 | Dec 31, 2024 | -$12.00M | – |
| Q3 FY2024 | Sep 30, 2024 | -$5.78M | – |
| Q2 FY2024 | Jun 30, 2024 | -$28.15M | – |
| Q1 FY2024 | Mar 31, 2024 | -$11.18M | – |
| Q4 FY2023 | Dec 31, 2023 | -$9.62M | – |
| Q3 FY2023 | Sep 30, 2023 | -$6.09M | – |
| Q2 FY2023 | Jun 30, 2023 | -$5.58M | – |
| Q1 FY2023 | Mar 31, 2023 | -$12.94M | – |
| Q4 FY2022 | Dec 31, 2022 | -$6.28M | – |
| Q3 FY2022 | Sep 30, 2022 | -$7.58M | – |
| Q2 FY2022 | Jun 30, 2022 | -$16.17M | – |
| Q1 FY2022 | Mar 31, 2022 | -$21.83M | – |
| Q4 FY2021 | Dec 31, 2021 | -$23.46M | – |
| Q3 FY2021 | Sep 30, 2021 | -$21.59M | – |
| Q2 FY2021 | Jun 30, 2021 | -$21.70M | – |
| Q1 FY2021 | Mar 31, 2021 | -$23.23M | – |
| Q4 FY2020 | Dec 31, 2020 | -$20.77M | – |
| Q3 FY2020 | Sep 30, 2020 | -$21.83M | – |
| Q2 FY2020 | Jun 30, 2020 | -$18.19M | – |
| Q1 FY2020 | Mar 31, 2020 | -$17.78M | – |
| Q4 FY2019 | Dec 31, 2019 | -$12.87M | – |
| Q3 FY2019 | Sep 30, 2019 | -$10.51M | – |
| Q2 FY2019 | Jun 30, 2019 | -$9.54M | – |
| Q1 FY2019 | Mar 31, 2019 | -$6.06M | – |
| Q4 FY2018 | Dec 31, 2018 | -$3.82M | – |
| Q3 FY2018 | Sep 30, 2018 | -$2.86M | – |
| Q2 FY2018 | Jun 30, 2018 | -$2.63M | – |
| Q1 FY2018 | Mar 31, 2018 | -$2.75M | – |
See a number that looks wrong?